Zykadia (Ceritinib)

Save 80% with Zykadia from insulinhub - called Zykadia or Spexib internationally.

According to the European Medicines Agency, brand name Zykadia/Spexib originating from Europe is manufactured at the following site(s):

Novartis Pharmaceutical Manufacturing LLC Verovškova ulica 57 1000 Ljubljana SloveniaNovartis Pharma GmbH Roonstraße 25 D-90429 Nuremberg GermanyLek farmacevtska družba d.d., Poslovna enota PROIZVODNJA LENDAVA Trimlini 2D 9220 Lendava Slovenia

Information about Zykadia (Ceritinib)

Zykadia (Ceritinib) is an oral medication used in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) gene rearrangement. It works by inhibiting the activity of the abnormal ALK protein that is involved in the growth of cancer cells.

Product Highlights

• Zykadia is primarily indicated for the treatment of ALK-positive, advanced, or metastatic non-small cell lung cancer (NSCLC) in patients who have previously been treated with crizotinib or other ALK inhibitors.
• It is used as a second-line therapy in patients who show resistance to crizotinib.

Key Ingredient

• Ceritinib

Key Benefits

• Zykadia targets cancer cells specifically with ALK mutations, minimizing damage to healthy cells.
• It can be effective in patients whose cancer has become resistant to other therapies, like crizotinib.
• Zykadia is taken in oral form, which is easier for patients compared to intravenous options.

Direction of Use

• Typically, Zykadia is taken as a once-daily oral dose, with or without food. The standard dosage is usually 750 mg daily, but it should be tailored to the individual’s response and tolerance.
• The capsule must be swallowed intact and should not be chewed or crushed. 
• Dose adjustments may be necessary based on liver function and side effects.

Recommended ZYKADIA Dose Reductions

Safety Concerns

• Liver function tests should be monitored before starting treatment and regularly thereafter, as ceritinib can cause elevated liver enzymes or liver damage.
• It can cause nausea, diarrhea, vomiting, and abdominal pain. Antiemetics or adjustments in dosing may be required to manage these side effects.
• Zykadia can prolong the QT interval, which may lead to serious heart issues, including arrhythmia.
• Interstitial lung disease (ILD) or pneumonitis has been reported. Patients should be monitored for respiratory symptoms.
• Visual disturbances have been observed in some patients taking Zykadia.

Avoid Zykadia (Ceritinib) If

• Patients with a known allergy to ceritinib or any of its ingredients should not use it.
• Patients with severe liver impairment should avoid using Zykadia unless instructed by their healthcare provider.
• Ceritinib is contraindicated during pregnancy and breastfeeding due to the potential for harm to the fetus or infant. Contraceptive measures should be used to prevent pregnancy during treatment.
• If you have a history of heart problems, such as prolonged QT interval, it is important to consult a healthcare provider before starting Zykadia.
• If you have a history of interstitial lung disease, Zykadia may not be suitable due to the risk of exacerbating lung issues.